Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229122 | 0.85 | — | — | |
| SCHEMBL14645381 | 0.81 | — | — | |
| SCHEMBL10956485 | 0.79 | — | — | |
| SCHEMBL7708782 | 0.77 | — | — | |
| SCHEMBL8813673 | 0.72 | CYP2C19 (0.40) | — | |
| SCHEMBL1995590 | 0.72 | — | — | |
| SCHEMBL20637 | 0.69 | — | — | |
| SCHEMBL21634042 | 0.62 | — | — | |
| SCHEMBL131287 | 0.61 | — | — | |
| SCHEMBL97707 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196936-A1 | POLYNUCLEOTIDE CANCER VACCINE COMPOSITIONS AND METHODS OF USING THE SAME | Imunon, Inc. (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2023196935-A1 | POLYNUCLEOTIDE VACCINE FORMULATIONS AND METHODS OF USING THE SAME | Imunon, Inc. (US) | 2023-10-12 | — | — | WO | claimed |
| EP-4221739-A1 | POLYNUCLEOTIDE VACCINES AND METHODS OF USING THE SAME | Imunon, Inc. (US) | 2023-08-09 | — | — | EP | claimed |
| US-8344177-B2 | Albumin binding molecules and uses thereof | PHILOCHEM AG (CH) | 2013-01-01 | — | — | US | claimed |
| US-20100172844-A1 | ALBUMIN BINDING MOLECULES AND USES THEREOF | PHILOCHEM AG (CH) | 2010-07-08 | — | — | US | claimed |
| EP-2094647-A2 | ALBUMIN BINDING MOLECULES AND USES THEREOF | Philochem AG (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008053360-A2 | ALBUMIN BINDING MOLECULES AND USES THEREOF | PHILOCHEM AG (CH) | 2008-05-08 | — | — | WO | claimed |
| EP-0888129-A4 | MAGNETIC RESONANCE BLOOD POOL AGENTS BOUND TO HUMAN SERUM ALBUMIN | MALLINCKRODT MEDICAL INC (US) | 1999-03-03 | — | — | EP | claimed |
| EP-0888129-A1 | MAGNETIC RESONANCE BLOOD POOL AGENTS BOUND TO HUMAN SERUM ALBUMIN | MALLINCKRODT MEDICAL, INC. (US) | 1999-01-07 | — | — | EP | claimed |
| US-5693308-A | Magnetic resonance blood pool agents bound to human serum albumin | MALLINCKRODT MEDICAL, INC. (US) | 1997-12-02 | — | — | US | claimed |
| WO-1997030733-A1 | MAGNETIC RESONANCE BLOOD POOL AGENTS BOUND TO HUMAN SERUM ALBUMIN | MALLINCKRODT MEDICAL, INC. (US) | 1997-08-28 | — | — | WO | claimed |
| WO-1997030734-A1 | MAGNETIC RESONANCE BLOOD POOL AGENTS | MALLINCKRODT MEDICAL, INC. (US) | 1997-08-28 | — | — | WO | claimed |
| US-4510318-A | DETOXIFICATION; BURN INJURIES; MUCOLYTIC AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1985-04-09 | — | — | US | claimed |
| CN-116916949-A | Polynucleotide vaccine and methods of use thereof | 伊穆农股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023196935-A1 | POLYNUCLEOTIDE VACCINE FORMULATIONS AND METHODS OF USING THE SAME | Imunon, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196936-A1 | POLYNUCLEOTIDE CANCER VACCINE COMPOSITIONS AND METHODS OF USING THE SAME | Imunon, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-0888129-A4 | MAGNETIC RESONANCE BLOOD POOL AGENTS BOUND TO HUMAN SERUM ALBUMIN | MALLINCKRODT MEDICAL INC (US) | 1999-03-03 | — | — | EP | disclosed |
| EP-0888129-A1 | MAGNETIC RESONANCE BLOOD POOL AGENTS BOUND TO HUMAN SERUM ALBUMIN | MALLINCKRODT MEDICAL, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5693308-A | Magnetic resonance blood pool agents bound to human serum albumin | MALLINCKRODT MEDICAL, INC. (US) | 1997-12-02 | — | — | US | disclosed |
| WO-1997030733-A1 | MAGNETIC RESONANCE BLOOD POOL AGENTS BOUND TO HUMAN SERUM ALBUMIN | MALLINCKRODT MEDICAL, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100172844-A1 | ALBUMIN BINDING MOLECULES AND USES THEREOF | ALB, FABP1, FABP2 | TSHR 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.